PT2279210T - Péptidos de direcionamento lisossomal e suas utilizações - Google Patents

Péptidos de direcionamento lisossomal e suas utilizações

Info

Publication number
PT2279210T
PT2279210T PT97437073T PT09743707T PT2279210T PT 2279210 T PT2279210 T PT 2279210T PT 97437073 T PT97437073 T PT 97437073T PT 09743707 T PT09743707 T PT 09743707T PT 2279210 T PT2279210 T PT 2279210T
Authority
PT
Portugal
Prior art keywords
lisosomal
utilizations
peptides
directional
lisosomal directional
Prior art date
Application number
PT97437073T
Other languages
English (en)
Inventor
H Lebowitz Jonathan
Maga John
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PT2279210T publication Critical patent/PT2279210T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT97437073T 2008-05-07 2009-05-07 Péptidos de direcionamento lisossomal e suas utilizações PT2279210T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5133608P 2008-05-07 2008-05-07
US14410609P 2009-01-12 2009-01-12

Publications (1)

Publication Number Publication Date
PT2279210T true PT2279210T (pt) 2017-07-10

Family

ID=41265422

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97437073T PT2279210T (pt) 2008-05-07 2009-05-07 Péptidos de direcionamento lisossomal e suas utilizações

Country Status (16)

Country Link
US (8) US20110223147A1 (pt)
EP (4) EP3778652A1 (pt)
JP (1) JP5627571B2 (pt)
CN (1) CN102066422B (pt)
AU (1) AU2009244148B2 (pt)
BR (2) BR122017015900A2 (pt)
CA (1) CA2723412A1 (pt)
CY (1) CY1119183T1 (pt)
DK (1) DK2279210T3 (pt)
ES (2) ES2629853T3 (pt)
HR (1) HRP20170698T1 (pt)
HU (1) HUE034850T2 (pt)
IL (1) IL209091A (pt)
PL (1) PL2279210T3 (pt)
PT (1) PT2279210T (pt)
WO (1) WO2009137721A2 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134853B1 (en) 2007-04-03 2018-07-18 Oxyrane UK Limited Glycosylation of molecules
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
ES2629853T3 (es) 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
EP2484371B1 (en) 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US9598682B2 (en) 2009-09-29 2017-03-21 Vib Vzw Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
SI2485761T1 (sl) 2009-10-09 2019-05-31 Armagen, Inc. Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
JP2013511272A (ja) 2009-11-19 2013-04-04 オキシレイン ユーケー リミテッド 哺乳類様複合ｎ−グリカンを生成する酵母株
AU2011270670B2 (en) 2010-06-25 2017-01-12 Takeda Pharmaceutical Company Limited Methods and compositions for CNS delivery of arylsulfatase A
EP2588130B1 (en) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
CA2805413A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of heparan n-sulfatase
UA115649C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс ідуронат-2-сульфатази
ES2896060T3 (es) 2010-06-25 2022-02-23 Shire Human Genetic Therapies Métodos y composiciones para la administración al SNC de arilsulfatasa A
NZ702801A (en) * 2010-06-25 2016-08-26 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
SG189110A1 (en) 2010-09-29 2013-05-31 Oxyrane Uk Ltd De-mannosylation of phosphorylated n-glycans
WO2012042386A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
CN102121021B (zh) * 2010-12-21 2012-05-02 南京师范大学 绵羊IFN-γ诱导的溶酶体巯基还原酶cDNA及其克隆方法和重组应用
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
CA3080181A1 (en) * 2011-03-04 2012-09-13 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
TR201802230T4 (tr) 2011-05-27 2018-03-21 Amicus Therapeutics Inc Lizozomal depo hastalıklarının gelişmiş tedavileri için hedefleyici peptitlerin rekombinan lizozomal enzimler üzerine kenetlenmesi için yöntemler.
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
JP6194324B2 (ja) 2012-03-15 2017-09-06 オキシレイン ユーケー リミテッド ポンペ病の処置のための方法および材料
WO2014082080A2 (en) * 2012-11-26 2014-05-30 Callidus Biopharma, Inc. Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
LT3115372T (lt) * 2012-11-27 2019-06-25 Biomarin Pharmaceutical Inc. Tiksliniai terapiniai lizosominio fermento sulieti baltymai ir jų panaudojimas
MX2017001898A (es) * 2014-08-11 2017-04-11 Shire Human Genetic Therapies Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales.
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
CN114540327B (zh) * 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
EP3220958A1 (en) * 2014-10-24 2017-09-27 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
MA41022A (fr) * 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
MX2018005258A (es) 2015-11-06 2019-09-04 Biomarin Pharm Inc Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas.
KR102747683B1 (ko) 2015-12-30 2024-12-31 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
IL261246B2 (en) 2016-02-24 2023-03-01 Biomarin Pharm Inc Therapeutic fusion proteins targeting lysosomal enzymes, their formulations and their uses
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
SI3448382T1 (sl) 2016-04-29 2021-03-31 Orphazyme A/S, c/o COBIS A/S Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
ES2950808T3 (es) 2017-05-15 2023-10-13 Amicus Therapeutics Inc Alfa-glucosidasa ácida humana recombinante
ES3065816T3 (en) 2017-06-07 2026-05-08 Regeneron Pharma Compositions and methods for internalizing enzymes
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
US10325665B2 (en) * 2017-12-08 2019-06-18 Intel Corporation Block by deck operations for NAND memory
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
JP7749322B2 (ja) 2018-04-30 2025-10-06 アミカス セラピューティックス インコーポレイテッド 遺伝子治療構築物及び使用方法
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
EA202190999A1 (ru) 2018-10-10 2021-10-15 Амикус Терапьютикс, Инк. Композиции на основе полипептидов, стабилизированных с помощью дисульфидной связи, и способы применения
AU2019381776A1 (en) * 2018-11-16 2021-07-01 AskBio Inc. Therapeutic adeno-associated virus for treating Pompe disease
US20220002688A1 (en) 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
CA3134485A1 (en) * 2019-04-30 2020-11-05 James M. Wilson Compositions useful for treatment of pompe disease
CN112546228A (zh) * 2019-09-10 2021-03-26 中国科学院上海营养与健康研究所 非igf1r结合型的物质在预防和/或治疗炎症性疾病中的应用
PH12022551229A1 (en) * 2019-11-19 2023-07-31 Asklepios Biopharmaceutical Inc Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
US12358963B2 (en) 2019-12-24 2025-07-15 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
CN113105526B (zh) * 2020-01-09 2022-04-26 北京鲲达宇科技有限公司 多肽及其应用、包括该多肽的探针、试剂盒
WO2022104261A1 (en) * 2020-11-16 2022-05-19 Avrobio, Inc. Compositions and methods for treating pompe disease
WO2022106614A1 (en) 2020-11-19 2022-05-27 Orphazyme A/S Processes for preparing arimoclomol citrate and intermediates thereof
WO2022194078A1 (zh) * 2021-03-15 2022-09-22 北京大学 用于靶分子修饰的缀合物及其制备方法
CA3223707A1 (en) 2021-06-21 2022-12-29 Hanadie Yousef Regenerative polypeptides and uses thereof
US20240279360A1 (en) 2021-06-23 2024-08-22 Lycia Therapeutics, Inc. Bifunctional compounds containing igf-2 polypeptides
CN117343197A (zh) * 2021-10-15 2024-01-05 中山大学 重组融合抗体
CN114404615B (zh) * 2022-02-11 2024-05-24 国家纳米科学中心 一种多肽纳米胶束制剂、其制备方法及应用
NL2031676B1 (en) 2022-04-22 2023-11-07 Univ Erasmus Med Ct Rotterdam Gene therapy for Pompe Disease
EP4611783A1 (en) 2022-11-01 2025-09-10 Erasmus University Rotterdam Medical Center Gene therapy constructs for metabolic disorders
WO2024108137A2 (en) 2022-11-18 2024-05-23 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
JP2026501731A (ja) 2023-01-06 2026-01-16 サイズミック セラピューティク インコーポレイテッド プロテアーゼ変異体及びその使用
WO2025171294A1 (en) * 2024-02-07 2025-08-14 University Of Massachusetts Lysosome-targeting chimeras and methods of use

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309776A (en) * 1980-05-13 1982-01-12 Ramon Berguer Intravascular implantation device and method of using the same
US4749570A (en) * 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1986000619A1 (en) * 1984-07-13 1986-01-30 Chiron Corporation Prepro insulin-like growth factors i and ii
CA1260858A (en) 1985-03-28 1989-09-26 Lawrence S. Cousens Expression using fused genes providing for protein product
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US5817623A (en) * 1995-03-06 1998-10-06 Univ Colorado State Res Found Method for treating diabetic peripheral neuropathy with IGF-I or IGF-II
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) * 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) * 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US6610299B1 (en) * 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5248606A (en) 1990-06-11 1993-09-28 Dowelanco Dna encoding inactive precursor and active forms of maize ribosome inactivating protein
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5633235A (en) * 1991-04-19 1997-05-27 Regents Of The University Of Michigan Triciribine and analogs as antiviral drugs
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
WO1993006216A1 (en) 1991-09-26 1993-04-01 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
CA2123307A1 (en) 1991-11-26 1993-06-10 Phillip M. Friden Process for the preparation of transferrin receptor specific antibody-neuro-pharmaceutical or diagnostic agent conjugates
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5981194A (en) * 1992-07-10 1999-11-09 University Of British Columbia Use of p97 and iron binding proteins as diagnostic and therapeutic agents
EP0652775B1 (en) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
US5476779A (en) * 1992-09-30 1995-12-19 University Of Maryland At College Park DNA encoding insulin-like growth factor II isolated from rainbow trout
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US20020013953A1 (en) * 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
ATE273020T1 (de) * 1995-09-29 2004-08-15 Biomarin Pharm Inc Verwendung von heparinasen zur verminderung von entzündungsreaktionen
US6348194B1 (en) * 1995-11-13 2002-02-19 Ixsys Incorporated Tumor specific internalizing antigens and methods for targeting therapeutic agents
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
CA2244228A1 (en) * 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6020144A (en) * 1996-09-12 2000-02-01 Symbiontics, Inc. Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6235874B1 (en) * 1997-01-10 2001-05-22 Academia Sinica Production of biologically active recombinant insulin-like growth factor II polypeptides
US6329501B1 (en) * 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
WO1998054665A1 (en) * 1997-06-02 1998-12-03 The Johns Hopkins University Computer method utilizing free energy calculations for ligand design and the prediction of binding targets
US6472140B1 (en) * 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
US6066626A (en) * 1997-10-29 2000-05-23 Genzyme Corporation Compositions and method for treating lysosomal storage disease
MXPA01001445A (es) * 1998-08-11 2002-11-29 Large Scale Biology Corp Metodo para recuperar proteinas a partir del fluido intersticial de tejidos de plantas.
CA2353522A1 (en) * 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
US6596500B1 (en) * 1998-12-08 2003-07-22 The General Hospital Corporation Binding of retinoids to M6P/IGF-II receptor
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6770468B1 (en) * 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6642038B1 (en) * 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) * 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
DK174076B1 (da) 2000-01-21 2002-05-21 Flowcon Int As Reguleringsindsats til anbringelse i ventiler og ventilenhed
US20020081654A1 (en) * 2000-04-07 2002-06-27 Sandrin Mauro Sergio Targeting hydrolase enzymes
DK1782825T3 (da) * 2000-07-18 2014-11-03 Univ Duke Behandling af glycogenlagringssygdom type II
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
WO2002044355A2 (en) 2000-11-30 2002-06-06 Symbiontics, Inc. Protozoan expression systems for lysosomal storage disease genes
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
EP1974752B1 (en) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
WO2003102583A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IL161352A0 (en) 2001-10-16 2004-09-27 Symbiontics Inc Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
WO2003086452A2 (en) * 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
JP4828121B2 (ja) * 2002-05-29 2011-11-30 バイオマリン ファーマシューティカル インコーポレイテッド 標的化治療的タンパク質
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
JP5433133B2 (ja) * 2003-01-22 2014-03-05 デューク・ユニヴァーシティ リソソームポリペプチドを発現するための改善された構築物
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20060078542A1 (en) * 2004-02-10 2006-04-13 Mah Cathryn S Gel-based delivery of recombinant adeno-associated virus vectors
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
AU2006203882B2 (en) * 2005-01-07 2011-05-12 Regeneron Pharmaceuticals, Inc. IGF-1 fusion polypeptides and therapeutic uses thereof
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
ATE511645T1 (de) * 2006-03-17 2011-06-15 Biomarin Pharm Inc Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
US8343918B2 (en) * 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
CA2680189A1 (en) * 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
ES2629853T3 (es) 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
EP2475376B1 (en) * 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
NZ702801A (en) * 2010-06-25 2016-08-26 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
LT3115372T (lt) * 2012-11-27 2019-06-25 Biomarin Pharmaceutical Inc. Tiksliniai terapiniai lizosominio fermento sulieti baltymai ir jų panaudojimas

Also Published As

Publication number Publication date
PL2279210T3 (pl) 2017-10-31
CY1119183T1 (el) 2018-02-14
US20110223147A1 (en) 2011-09-15
EP3778652A1 (en) 2021-02-17
EP3187508A1 (en) 2017-07-05
EP3272773B8 (en) 2020-11-18
BR122017015900A2 (pt) 2019-09-10
US11351231B2 (en) 2022-06-07
US20180125949A1 (en) 2018-05-10
CN102066422B (zh) 2015-07-22
JP2011521627A (ja) 2011-07-28
IL209091A0 (en) 2011-01-31
EP3272773B1 (en) 2020-07-08
US20120213762A1 (en) 2012-08-23
ES2830350T3 (es) 2021-06-03
US20210069304A1 (en) 2021-03-11
US8563691B2 (en) 2013-10-22
WO2009137721A3 (en) 2010-04-08
EP3187508B1 (en) 2026-04-22
WO2009137721A2 (en) 2009-11-12
AU2009244148A1 (en) 2009-11-12
BRPI0912225A2 (pt) 2018-03-20
AU2009244148B2 (en) 2014-10-09
EP2279210B1 (en) 2017-04-12
EP2279210A4 (en) 2011-09-14
CA2723412A1 (en) 2009-11-12
IL209091A (en) 2015-04-30
ES2629853T3 (es) 2017-08-16
US20230241187A1 (en) 2023-08-03
US9469683B2 (en) 2016-10-18
HRP20170698T1 (hr) 2017-09-22
US20170007680A1 (en) 2017-01-12
CN102066422A (zh) 2011-05-18
HK1250042A1 (en) 2018-11-23
DK2279210T3 (en) 2017-07-24
EP2279210A2 (en) 2011-02-02
US20150064157A1 (en) 2015-03-05
JP5627571B2 (ja) 2014-11-19
EP3272773A1 (en) 2018-01-24
HUE034850T2 (en) 2018-03-28
US20220354934A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
EP2215246A4 (en) PROTEIN SCAFFOLDS
DK3118220T3 (da) Protein
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
EP2233952A4 (en) OMNIDIRECTIONAL RAINMETER INSTRUMENT
ATE543405T1 (de) Frisiergerät
BRPI0814587A2 (pt) Peptídeos antibióticos
EP2220838A4 (en) SOFTWARE-DEFINED RADIO ARCHITECTURE
EP3988147C0 (en) INSERT SET
HRP20170698T1 (hr) Lizosomski usmjereni peptidi i njihove uporabe
HRP20151120T1 (xx) Polipeptid ace2
FI20095373L (fi) Antenni
BRPI0814971A2 (pt) Proteína
DK3115370T3 (da) Biologisk aktive peptider
BRPI0807137A2 (pt) Agentes antiparasitários
BRPI0915367A2 (pt) peptídeos e epítopos anti-p2x7
EP2111418A4 (en) Hollow microparticles
EP2345301A4 (en) SOFTWARE-DEFINED RADIO
DK2155273T3 (da) Lugtregulerende genstand
BRPI0921289A2 (pt) Combinações pesticidas
BRPI0909036A8 (pt) pesticidas
BRPI1010661A2 (pt) peptídeo
BRPI0907825A2 (pt) Combinações pesticidas
HRP20150195T1 (xx) Antibakterijski peptidi
FI20065144L (fi) Suuntakytkin
FI20075275A0 (fi) RF-transkonduktanssituloaste